newsfilter
← Latest News
Business Wire·

PhaseBio Pharmaceuticals to Host Virtual Investor and Analyst Day on March 15, 2021

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it will host a virtual Investor and Analyst Day on March 15, 2021 from 12:00 p.m. to 2:00 p.m. ET. The event will focus on an overview of the bentracimab development program, including current enrollment status for the ongoing global Phase 3 REVERSE-IT trial. Bentracimab is a novel, human monoclonal antibody fragment that in earlier trials has shown immediate and sustained reversal of the antiplatelet effects of Brilinta® (ticagrelor).